Resource KT
Related Articles
JERUSALEM, July 6, 2021 / PRNewswire / – Alpha Tau Medical, Developer of Pioneering Alpha Radiation Cancer Therapy Alpha DaRT™, announced today that the first participant in its U.S. skin cancer pilot trial was treated with Alpha DaRT, at the University Cancer Center in Houston, texas. the Houston site, led by radiation oncologist Dr Mark A. D’Andrea, is part of a larger multicenter study that began as a single-center trial at Memorial Sloan Kettering Cancer Center (MSK) in New York City. This first patient marks another milestone for Alpha Tau, following its “breakthrough device designation” received from the FDA last month, allowing an accelerated regulatory path in United States.
CEO of Alpha Tau Uzi sofer said, “We are delighted to have treated our first patient in the critical US market, after expanding our MSK trial to new sites, including the University Cancer Center in Houston. As we had hoped, following the breakthrough device designation, our clinical studies are starting to progress rapidly and we plan to treat patients at other US sites in the near future, which we believe will confirm the promising results. that we have seen so far in our other trials around the world. “
“With our international clinical studies program which is already progressing in Israel, Japan, Italy and Russia, we look forward to delivering results in our US multi-center trial, including the site led by Dr D’Andrea and his experienced team, ”said Alpha Tau CMO, Dr. Robert den. “We hope to complete our pilot safety and feasibility trial for Alpha DaRT in skin cancer patients in the near future, then move to a larger pivotal study to receive market approval from Alpha DaRT.” American.
Mark D’Andrea, MD is the oncologist leading the introduction of advanced Alpha DaRT technology at the University Cancer Center in Houston, texas. He commented: “It is exciting and inspiring to be involved in this study, which uses powerful alpha radiation to treat patients who have new cancers, those who have failed previous treatment or who cannot be treated. by conventional therapies. Unlike surgery or long courses of radiation therapy, with Alpha DaRT the patient receives treatment and goes home the same day. Alpha DaRT can also potentially prevent extensive surgical wounds or be used to treat cancers near organs. reviews, for which traditional radiation therapy might be too risky. The exceptional team at Alpha Tau provided a smooth integration process and made this revolutionary new type of cancer therapy easy to use. Several patients have been recruited to our site, and after treating our first patient today with head and neck skin cancer, we look forward to helping more patients using the Alpha soon. DaRT. “
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau Medical Ltd, is an Israeli oncology therapy company focused on the research, development and commercialization of Alpha DaRT ™ technology for the treatment of solid tumors.
Alpha DaRT ™ (Diffusing Alpha-Emitters Radiation Therapy) is an innovative technology that enables the unique highly potent and conformal alpha irradiation of solid tumors. The treatment is delivered by intratumoral insertion of Radium-224 radionuclide, which leads to the release and diffusion of daughter radioisotopes which emit alpha particles. These alpha particles have the ability to destroy solid tumors. Since alpha emitting atoms only diffuse a short distance into tissue, Alpha DaRT primarily damages the tumor, while sparing the healthy tissue around it.
Contact:
Amnon Gat
Phone. : +1 833-455-3278
Media package: https://www.dropbox.com/sh/4wtkdggbyatxyly/AACobJHTz_OD2dNE3Z0cYKc1a?dl=0
Logo – https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg
Show original content:https://www.prnewswire.com/news-releases/first-alpha-dart-patient-related-in-the-us-as-part-of-pilot-multicenter-skin-cancer-trial-301326289.html
SOURCE Alpha Tau Medical
